Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ: BSCT)

에 대한 최신 뉴스 Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ:BSCT)

The Fund generally will invest at least 80 percent of its total assets in securities that comprise the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, Invesco Indexing LLC (the Index Provider) compiles and maintains the Underlying Index. The Underlying Index seeks to measure the performance of a portfolio of U.S. dollar-denominated investment grade corporate bonds with maturities or, in some cases, effective maturities in the year 2029 (collectively, 2029 Bonds). Certain bonds in which the Fund may invest may contain embedded issuer call options. An embedded issuer call option means that the bonds issuer has the right to redeem a bond prior to its designated maturity date.

Invesco BulletShares 2029 Corporate Bond ETF

Jefferies analyst Philippe Houchois downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Buy to Hold and maintains the price target from $16 to $16.

News

Downgrades

Price Target

Analyst Ratings

RIVN

Jefferies Downgrades Rivian Automotive to Hold, Maintains Price Target to $16

Contracts

Jacobs Was Selected As The Integrated Delivery Partner For Marinus Link, An Approximately 214 Mile (345-kilometer) Undersea And Underground High-voltage Direct Current (Hvdc) Electricity And Data Interconnector

Needham analyst Bernie McTernan reiterates Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Hold to Hold.

Reiteration

ABNB

Needham Reiterates Hold on Airbnbto Hold

Jefferies analyst Ashley Helgans upgrades PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Hold to Buy and raises the price target from $70 to $105.

Upgrades

Jefferies Upgrades PVH to Buy, Raises Price Target to $105

Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANF#OTC">NSANF</a>) announced major steps to reconfigure its global operations after a challenging financial year. The company said on Tuesday that it will slash thousands of jobs and close almost half of its production plants across the globe, as part of a multi-year restructuring plan targeted towards stabilizing its bottom line.
What Happened: The company shared plans to terminate nearly 15% of its workforce, which entails approximately 20,000 employees, by fiscal year 2027. This includes the 9,000 job cuts announced earlier. In addition, Nissan will also shrink its global manufacturing footprint, reducing the number of factories from 17 to 10 over two years.
Last week, reports emerged that the <a href="https://www.benzinga.com/news/25/05/45316137/nissan-scraps-11-billion-ev-battery-plant-eyes-cost-cuts-to-survive-report">company is canceling its plans</a> to establish a $1.1 billion electric vehicle battery factory in Kitakyushu, Japan.
See Also: <a href="https://www.benzinga.com/25/05/45250949/tech-layoffs-get-the-headlines-but-its-uncle-sam-doge-whos-bleeding-workers-in-2025">Intel, Meta Get The Headlines, But It&#8217;s Uncle Sam (DOGE) Who&#8217;s Bleeding Workers In 2025</a>
Why It Matters: Nissan faced a $4.5 billion loss in 2024, citing rising variable costs and ongoing global turmoil. "In the face of challenging FY24 performance and rising variable costs, compounded by an uncertain environment, we must prioritize self-improvement with greater urgency and speed," said CEO Ivan Espinosa. The company also noted it would prioritize U.S.-made products and move operations to <a href="https://www.benzinga.com/news/25/05/45316137/nissan-scraps-11-billion-ev-battery-plant-eyes-cost-cuts-to-survive-report">sidestep tariff-related pressures</a>.
"We are taking a prudent approach to reassess our targets and actively seek every possible opportunity to implement and ensure a robust recovery," Espinosa added.
Nissan was not the only major company to announce layoffs on Tuesday. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) shared on the same day that it will cut <a href="https://www.benzinga.com/markets/equities/25/05/45398101/microsoft-to-cut-6000-jobs-in-global-restructuring-joins-meta-and-amazon-in-trimming-workforce-amid-ai-driven-shift">6,000 jobs worldwide</a>, amounting to about 3% of its total workforce.
Price Action: Nissan Motor stock closed at 354 JPY ($2.42) on the Tokyo Stock Exchange on Wednesday, down 0.70% for the day. Year to date, the stock has declined 25.44%.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a></li>
</ul>
Image Via Shutterstock

Asia

Equities

Markets

Tech

General

MSFT

NSANF

NSANY

Nissan To Cut 20,000 Jobs, Shut 7 Plants Globally In Major Restructuring After $4.5 Billion Annual Loss

TSAT

Telesat And Arab Satellite Communications Organization Announced The Companies Have Successfully Negotiated And Signed A Term Sheet For A Multi-Gbps Capacity Pool Of Telesat Lightspeed Connectivity Services

Needham analyst Quinn Bolton reiterates Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) with a Buy and maintains $1.5 price target.

PXLW

Needham Reiterates Buy on Pixelworks, Maintains $1.5 Price Target

LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.38) by 65.79 percent. This is a 550 percent decrease over losses of $(0.02) per share from the same period last year.

Earnings

Earnings Beats

LVTX

LAVA Therapeutics Q1 EPS $(0.13) Beats $(0.38) Estimate

Needham analyst Mike Matson upgrades Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) from Hold to Buy and announces $48 price target.

ESTA

Needham Upgrades Establishment Labs Hldgs to Buy, Announces $48 Price Target

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has surged 65% over the past month, sharply outperforming other digital assets after a prolonged stretch of <a href="https://www.benzinga.com/money/btc-vs-eth">underperformance relative to Bitcoin</a>.
What Happened: According to a new report by Bernstein on Wednesday, the rebound is being driven by a convergence of structural and tactical catalysts.
The rally, they argue, is underpinned by three primary trends: renewed focus on blockchain utility via stablecoins, rising institutional interest in Ethereum's Layer 2 ecosystems and a major unwind of bearish hedge fund positioning.
"Stablecoins are bringing back the focus on underlying blockchain networks becoming platform proxies to gain exposure to the growth trend," the report said. 
Ethereum currently accounts for 51% of minted stablecoin supply, making it a key infrastructure layer for this segment.
The second catalyst revolves around the Layer 2 chains built on Ethereum. 
"Layer 2 chains use ETH for gas fees as underlying currency, thus helping drive distribution and demand for ETH," Bernstein noted, pointing to Base's $85 million in annual sequencer fees and Robinhood's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) recent acquisition of WonderFi as indicators of broader adoption. 
Also Read: <a href="https://www.benzinga.com/markets/25/05/45388118/bitcoin-taps-105-000-heres-when-it-could-hit-122-000">Bitcoin Taps $105,000: Here&#8217;s When It Could Hit $122,000</a>
This model, Bernstein says, "might become the template for asset managers and institutional users launching their own layer 2 chain on Ethereum."
Lastly, the report highlights a more tactical reason for Ethereum's strength: a repositioning among crypto hedge funds. 
"For the last 12-18 months, ETH was the perfect delta-neutral hedge. Crypto hedge funds were long Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and short ETH," the analysts wrote.
What&#8217;s Next: As the narrative now shifts toward blockchain utility and institutional adoption, these shorts are being closed.
The broader implication of Ethereum's rally is also positive for the digital asset ecosystem at large. 
"Resurgence of ETH and non-Bitcoin assets is also good for crypto exchanges and broker-dealers, as a broader crypto market rally reinvigorates retail traders," Bernstein said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45387228/can-the-us-china-tariff-de-escalation-send-bitcoin-ethereum-to-new-highs">Can The US-China Tariff De-Escalation Send Bitcoin, Ethereum To New Highs?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

HOOD

3 Key Drivers Behind Ethereum's 65% Rally: Bernstein

Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 27.27 percent increase over losses of $(0.22) per share from the same period last year.

GANX

Gain Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate

Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) affirms FY2025 sales outlook from $380.00 million to $380.00 million vs $389.93 million estimate.

Guidance

NEXN

Nexxen International Affirms FY2025 Contribution ex-TAC of approximately $380 million

AFC Gamma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.25 by 16 percent. This is a 57.14 percent decrease over earnings of $0.49 per share from the same period last year.

Earnings Misses

AFCG

AFC Gamma Q1 Adj. EPS $0.21 Misses $0.25 Estimate

WIIM

KRMN

Karman Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

CLBT

Cellebrite DI shares are trading lower after the company reported mixed Q1 financial results and cut its FY25 sales guidance with its midpoint below estimates. Also, the company issued Q2 sales guidance with its midpoint below estimates.

Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $1.76 million which missed the analyst consensus estimate of $1.78 million by 0.84 percent. This is a 15.14 percent increase over sales of $1.53 million the same period last year.

ABUS

Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate

Needham analyst Gil Blum reiterates Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy and maintains $9 price target.

ABSI

Needham Reiterates Buy on Absci, Maintains $9 Price Target

Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.05 by 220 percent. This is a 700 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $78.33 million which beat the analyst consensus estimate of $76.60 million by 2.26 percent. This is a 5.24 percent increase over sales of $74.43 million the same period last year.

Nexxen International Q1 Adj. EPS $0.16 Beats $0.05 Estimate, Sales $78.33M Beat $76.60M Estimate

Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 15.79 percent decrease over losses of $(0.38) per share from the same period last year.

INZY

Inozyme Pharma Q1 EPS $(0.44) Misses $(0.41) Estimate

Pony AI Inc. ("Pony.ai" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that Dr. Jun Peng, Chairman of the Board, Co-founder, and CEO, and Dr. Tiancheng Lou, Co-founder and CTO, have each entered into voluntary extended lock-up agreements (the "Extended Lock-Ups"). These agreements cover all shares of the Company's share capital or securities convertible into, exchangeable, or exercisable for any shares of the Company's share capital directly or indirectly owned by the co-founders for a period of 540 days starting from May 25, 2025, the expiration date of the Company's initial public offering lock-up period.
The Extended Lock-Ups cover a total of 110,828 Class A ordinary shares and 81,088,770 Class B ordinary shares, representing approximately 22.9% of the Company's total issued and outstanding ordinary shares as of the date of this announcement.

Comments

Invesco BulletShares 2029 Corporate Bond ETF

뉴스

에 대한 최신 뉴스 Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ:BSCT)

뉴스

파트너 / 기고자

벤징가 글로벌